Designates March of each year as "Fibromuscular Dysplasia Awareness Month."
The designation of a specific awareness month for FMD has the potential to positively impact recognition and understanding of the disease. By encouraging public officials and citizens to engage in activities that spread knowledge, the resolution seeks to alleviate the sense of isolation often felt by those affected. The Fibromuscular Dysplasia Society of America (FMDSA), which has been active in promoting awareness since its establishment in 2003, supports this initiative. Such recognition aims to highlight the challenges faced by FMD patients, including delays in diagnosis and treatment options, as well as the detrimental effects of misdiagnosis, which can lead to severe health consequences.
Assembly Joint Resolution No. 168 designates March of each year as 'Fibromuscular Dysplasia Awareness Month' in New Jersey. The bill aims to raise awareness about Fibromuscular Dysplasia (FMD), a rare disease characterized by abnormal growth in the arterial wall, leading to complications such as narrowing, beading, and even tearing of arteries. FMD primarily affects women, and it is estimated that about 4-5% of the population may be diagnosed with the condition, although it remains largely under-diagnosed due to a lack of awareness and understanding within both the public and the medical community. The resolution calls for appropriate observances and activities to be held in recognition of this month, emphasizing education about the disease.
While the intent of the resolution is widely seen as beneficial, potential contention may arise regarding the effectiveness of awareness months in producing tangible changes in medical practices and funding for research. Critics may argue that designating a month does not address the systemic issues related to the diagnosis and treatment of rare diseases like FMD. Additionally, discussions around budget allocations for public health initiatives could arise, especially in a climate where healthcare resources are often limited. Despite these concerns, the overall sentiment towards AJR168 appears to be one of support for increasing visibility for those suffering from FMD.